A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2891825792
